



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone: 0091-11-26494519-24
E-mail: admin@jagsonpal.com

JPL/SEC/RESU-NOT

Date : May 13th, 2011

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041


SUB: UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31.03.2011 & Limited Review.

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith unaudited financial results (provisional) for the quarter ended 31st March, 2011 and Limited Review.

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**


(S.K. MATA)



COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 31.03.2011

Particulars	Quarter ended 31.03.2011 Unaudited	Quarter Ended 31.03.2010 Unaudited	12 Months Ended 31.03.2011 Unaudited	Rs. in lacs 12 Months ended 31.03.2010 Audited
1a Net sales/Income from Operations	3185.05	3957.77	16095.02	13959.34
1b Other Operating Income				
Total	3185.05	3957.77	16095.02	13959.34
2 Expenditure				
a. (Inc.)/Dec. in Stock in trade & work in progress	-643.34	-230.66	192.46	-1042.09
b. Consumption of Raw Materials	2091.41	2430.37	7143.54	7219.40
c. Purchase of traded goods	161.06	20.01	963.95	1372.92
d. Employees Cost	750.13	600.41	3222.70	2378.78
e. Depreciation	45.35	50.01	211.80	208.50
f. Other Expenditure	699.62	652.31	3147.55	2458.50
g. Total	3104.23	3522.45	14882.00	12596.01
3 Profit from Operations before Other Income, Interest and	80.82	435.32	1213.02	1363.33
4 Other Income	25.31	29.89	25.31	36.30
5 Profit before Interest and Exceptional items (3+4)	106.13	465.21	1238.33	1399.63
6 Interest	50.65	84.34	332.11	349.62
7 Profit after Interest but before Exceptional Items (5-6)	55.48	380.87	906.22	1050.01
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	55.48	380.87	906.22	1050.01
10 Tax expense	16.50	24.69	188.50	125.81
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	38.98	356.18	717.72	924.20
12 Extraordinary Items (net of tax expense)				
13 Net Profit(+)/Loss(-) for the period(11-12)	38.98	356.18	717.72	924.20
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance				6049.30
16 Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	0.15	1.36	2.74	3.53
b. Basic & diluted EPS after extraordinary items for the	0.15	1.36	2.74	3.53
17 Public shareholding :				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding				
A Pledged / encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of	-	-	-	-
- Percentage of shares (as a % of the total share capital of	-	-	-	-
B Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 31.03.2011 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-5-2011
- No complaints were pending at the beginning/end of the quarter ended 31.03.2011. However 45 requests for change of address/dividend revaluation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

Place : New Delhi
Date : 13.5.2011



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre,
Babar Road, New Delhi - 110 001
Ph. (O) : 23413486
E-mail : sureshsethi62@yahoo.com

TO WHOM IT MAY CONCERN

We have reviewed the accompanying statement of un-audited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 31.03.2011. This statement is the responsibility of the Company's management and has been approved by the Audit Committee and Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial statement issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not excess an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : New Delhi
Date : 13/05/2011

for P. P. THUKRAL & CO.,
Chartered Accountants


SURESH SETHI
PARTNER
M.No. 089318